NICE reveals new standards for digital techNICE has published new standards setting out the requirements needed to develop digital health technologies for the NHS Share XNICE reveals new standards for digital techhttps://pharmaphorum.com/news/nice-reveals-new-standards-for-digital-tech/
Generics firms the ‘biggest cartel in US history’ – reportUS authorities looking into price fixing in the generics industry are now investigating 16 companies and the price Share XGenerics firms the ‘biggest cartel in US history’ – reporthttps://pharmaphorum.com/news/generics-firms-the-biggest-cartel-in-us-history-report/
Akorn searches for new CEO after failed Fresenius mergerUS generics firm Akorn is searching for a new CEO in the wake of a failed merger with Share XAkorn searches for new CEO after failed Fresenius mergerhttps://pharmaphorum.com/news/akorn-searches-for-new-ceo-after-failed-fresenius-merger/
Certain brain tumours could respond to immunotherapySome brain tumours may respond to immunotherapy after all, according to a new study. So far, brain tumours Share XCertain brain tumours could respond to immunotherapyhttps://pharmaphorum.com/news/certain-brain-tumours-could-respond-to-immunotherapy/
Boehringer follows Sanofi with job cuts in FranceBoehringer Ingelheim has confirmed it plans to axe more than 10% of its workforce in France, or more Share XBoehringer follows Sanofi with job cuts in Francehttps://pharmaphorum.com/news/boehringer-follows-sanofi-with-job-cuts-in-france/
Fishawack acquires marketing consultancy Blue Latitude HealthPictured: Dominic Miller, Fred Bassett, Oliver Dennis (back row from left to right), Martin Brass, Gail Flockhart (front row Share XFishawack acquires marketing consultancy Blue Latitude Healthhttps://pharmaphorum.com/news/fishawack-acquires-marketing-consultancy-blue-latitude-health/
Merck KGaA links with AI firm to iron out side-effects during R&DGermany’s Merck KGaA has begun a licensing agreement with Canadian pharma R&D company Cyclica using artificial intelligence (AI) Share XMerck KGaA links with AI firm to iron out side-effects during R&Dhttps://pharmaphorum.com/news/merck-kgaa-links-with-ai-firm-to-iron-out-side-effects-during-rd/
AZ and CRUK team up to go all-in on CRISPRAstraZeneca and Cancer Research UK are collaborating to launch a centre of excellence in genetic screening, cancer modelling Share XAZ and CRUK team up to go all-in on CRISPRhttps://pharmaphorum.com/news/az-cruk-crispr/
Gilead hires Roche’s pharma chief Daniel O’Day as CEORoche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO Share XGilead hires Roche’s pharma chief Daniel O’Day as CEOhttps://pharmaphorum.com/news/gilead-hires-roches-pharma-chief-daniel-oday-as-ceo/
